DENTSPLY SIRONA (XRAY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 27. Analyst Michael Cherny from Leerink Partners reiterated a Hold rating on the stock and has a $19.00 price target.
Michael Cherny has given his Hold rating due to a combination of factors affecting DENTSPLY SIRONA’s current and future performance. The company is undergoing a challenging period marked by difficult market conditions and internal restructuring efforts. Despite some positive developments, such as growth in the SureSmile segment and unexpected gains in Equipment & Instruments, the overall performance indicates that the company’s turnaround is still in progress.
The stock is currently undervalued and produces solid free cash flow, which provides some downside protection. However, the tough market environment and mixed business performance make it difficult to identify a clear path for significant upside potential. Although cost-cutting measures might eventually lead to improved earnings, the uncertainty surrounding the company’s growth prospects and the need for further visibility in its strategic direction justify maintaining a Hold rating. Therefore, the price target has been adjusted from $21 to $19, reflecting these considerations.
In another report released on February 28, Robert W. Baird also maintained a Hold rating on the stock with a $20.00 price target.
XRAY’s price has also changed moderately for the past six months – from $25.390 to $17.150, which is a -32.45% drop .